Quantum BioPharma Ltd. (NASDAQ: QNTM) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application to initiate a Phase 2 clinical trial of Lucid-MS in people with multiple sclerosis. The randomized, double-blind, placebo-controlled trial will evaluate the company’s lead drug candidate, also known as Lucid-21-302, which is designed to inhibit peptidyl arginine deiminase 2 (PAD2) and target demyelination rather than broadly suppressing the immune system. The FDA clearance marks a critical step forward for Quantum BioPharma as it prepares Lucid-MS for its first clinical testing in MS patients.
Lucid-MS is a patented, first-in-class new chemical entity that has previously completed Phase 1 testing in healthy volunteers, with the company reporting favorable safety and tolerability. Preclinical models have shown the drug candidate to both prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. This mechanism of action distinguishes Lucid-MS from existing MS therapies, which primarily modulate or suppress the immune system. By focusing on demyelination, Quantum BioPharma aims to address a root cause of MS disability progression.
The company’s research efforts extend beyond its own laboratories. Quantum BioPharma is collaborating with scientists at Massachusetts General Hospital and Harvard Medical School on a PET imaging tracer designed to quantify demyelination. This collaboration could provide valuable biomarkers for assessing treatment response in MS and other neurodegenerative conditions. The FDA clearance and ongoing research have attracted analyst attention, with Rodman & Renshaw initiating coverage of Quantum BioPharma with a Buy rating and an $8 price target. The editorial coverage places Quantum BioPharma alongside broader biopharmaceutical developments involving Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN), spanning vaccines, ophthalmology, and neurological diseases. For investors, the FDA clearance represents a significant de-risking event and a potential catalyst for the company’s pipeline.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS. The company also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and royalty rights of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. To view the full press release, visit https://ibn.fm/cwPHa. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
